Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2012, Pages

  Breen, Lil ^a   Aswani, Nivedita ^b  

^a ARROWE PARK HOSPITAL   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADVERSE OUTCOME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; COMPARATIVE EFFECTIVENESS; CYSTIC FIBROSIS; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG RESPONSE; ELECTIVE INTRAVENOUS ANTIBIOTIC THERAPY; HUMAN; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM CULTURE; SURVIVAL RATE; SYMPTOMATIC INTRAVENOUS ANTIBIOTIC THERAPY; SYSTEMATIC REVIEW; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; INJECTIONS, INTRAVENOUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84866455727     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002767.pub2     Document Type: Review

References (26)

1. Brett MM, Simmonds EJ, Ghoneim ATM, Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Archives of Disease in Childhood 1992;67(9):1086-8. 2961075
2. Elborn JS, Prescott R, Stack B, Shale DJ, Pantin C, Ali N, et al. A comparison of the clinical outcome of symptomatic and elective regular intravenous antibiotics in the treatment of cystic fibrosis [abstract]. Thorax 1997;52(Suppl 6):A4. 2961077
3. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, Pantin C, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs [abstract]. Pediatric Pulmonology 2000;30(5):434. 2961078
4. Elborn JS, Prescott RJ, Stack BHR. The British Thoracic Society study of elective versus symptomatic treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis: 5 year results [abstract]. Proceedings of the 13th International Cystic Fibrosis Congress 2000 June 4-8; Stockholm. 2000:172. 2961080
5. Elborn JS, Prescott RJ, Stack BHR, Goodchild MC, Bates J, Pantin C, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000;55(5):355-8. 2961079
6. De Boeck K, Sauer K, Vandeputte S. Meropenem versus ceftazidime plus tobramycin for pulmonary disease in CF patients [abstract]. Netherlands Journal of Medicine 1999;54(Suppl):S39. 2961082
7. Nikolaizik WH, Vietzke D, Ratjen F. A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. Canadian Respiratory Journal 2008; Vol. 15, issue 5:259-62. 2961084
8. Nikolaizik WH, Vietzke D, Ratjen F. Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients [abstract]. European Respiratory Journal 2005;26(Suppl 49):620s. 2961085
9. Nikolaizik WH, Vietzke D, Ratjen F. Comparison of tobramycin 80mg (IV-preparation) and 300mg solution inhaled twice daily for chronic P. aeruginosa infection [abstract]. Journal of Cystic Fibrosis 2005;4 Suppl:S53. 6203225
10. Bauernfeind A, Marks MI, Strandvik B. Cystic Fibrosis Pulmonary Infections; Lessons from around the World. Basel: Verlag, 1996.
11. Brett MM, Ghonheim ATM, Littlewood JM. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis. Archives of Disease in Childhood 1986;61(11):1114-20.
12. Brett MM, Ghonheim ATM, Littlewood JM. Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection. Archives of Disease in Childhood 1987;62(4):357-61.
13. Brett MM, Ghonheim ATM, Littlewood JM. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis in a follow-up study. Journal of Clinical Microbiology 1988;26(8):1565-70.
14. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. Archives of Disease in Childhood 1997;77(6):493-6.
15. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002007.pub2]
16. Fitzsimmons SC. The changing epidemiology of cystic fibrosis. Journal of Pediatrics 1993;122(1):1-9.
17. FitzSimmons SC. The Cystic Fibrosis Foundation Patient Registry Report 1996. Pedriatric Pulmonology 1996;21:267-75.
18. Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish Center-treated cystic fibrosis patients: Results of aggressive treatment. Pediatric Pulmonology 1996;21(3):153-8.
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
20. Levy SB. Antimicrobial resistance: bacteria on the defence. BMJ 1998;317(7159):612-3.
21. Pedersen SS, Jensen T, Hoiby N, Koch N. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatrica Scandinavica 1987;76(6):955-61.
22. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometric 1975;31(1):103-15.
23. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment in controlled trials. JAMA 1995;273(5):408-12.
24. Szaff N, Flensberg EW. Pulmonary Pathology. In: Hodson ME, Norman AP editor(s). Cystic Fibrosis. London: Balliere-Tindall, 1983:31-51.
25. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338(8769):725-6.
26. Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002767]